ASLMS: CellFX from Pulse Offers Durable Clearance of SH Lesions

The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting. Additionally, a poster abstract reports positive results clearing refractory focal epithelial hyperplasia (FEH) on the lips with the Nano-Pulse Stimulation™ (NPS™) procedure.

In a study for the treatment of Sebaceous Hyperplasia (SH), presented by investigator Girish Munavalli, MD, investigators reported that 73% of lesions treated with NPS had maintained or improved clearance at 12-months, with good cosmesis.

“It is impressive to see the long-term response of lesion clearance achieved in this study of NPS technology for Sebaceous Hyperplasia,” says Dr. Munavalli, medical director and founder of Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte. “These results demonstrate a high degree of efficacy and durable results that clearly sets this cellular-specific procedure apart from other treatment options used to remove lesions.”

The presented case of FEH involves a patient who had failed previous treatments for the condition, which is caused by a specific human papilloma virus (HPV) infection in the mouth that can be difficult to treat and is prone to recurrence.

“We are delighted to participate in the ASLMS meeting this year where dermatology thought leaders continue to demonstrate the clinical efficacy and safety of the CellFX procedure to clear challenging benign lesions,” says Kevin Danahy, Chief Commercial Officer of Pulse Biosciences. “As we strive to help patients regain confidence in the appearance of their skin by removing unwanted benign lesions, we look forward to connecting with ASLMS members to discuss the high clinical and commercial value of our nonthermal, cellular-focused, CellFX System powered by NPS technology.”